Invention Grant
- Patent Title: Humanized antibodies with increased stability
-
Application No.: US17376314Application Date: 2021-07-15
-
Publication No.: US12227569B2Publication Date: 2025-02-18
- Inventor: Laurent Gauthier , Nicolas Schneider
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: SALIWANCHIK, LLOYD & EISENSCHENK
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K9/00 ; A61K39/00 ; A61K39/395 ; A61K47/02 ; A61K47/12 ; A61K47/26 ; C07K16/30
Abstract:
The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
Public/Granted literature
- US20210340254A1 HUMANIZED ANTIBODIES WITH INCREASED STABILITY Public/Granted day:2021-11-04
Information query
